JAMA Network Home
Sign In
Original Investigation

Cancer Biologics Utilization After Biosimilar Entry and Financial Implications For Payers and Patients

JAMA Oncology 10.1001/jamaoncol.2026.3128

August 27, 2026 at 11:00 AM EDT

Read the full article

The results of this cohort study suggest that biosimilar entry was associated with lower ASP and reduced market share for reference biologics in oncology. Market competition introduced by biosimilars was also associated with lowered payer costs and reduced patient financial burden.

Corresponding Author: Ya-Chen Tina Shih, PhD, 650 Charles Young Drive South, A2-125 CHS, BOX 956900. Los Angeles, CA 90095-6900 (tinashih@mednet.ucla.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

https://jamanetwork.com/journals/jamaoncology/fullarticle/10.1001/jamaoncol.2026.3128?utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_term=082726

Copy to clipboard

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.

Editor's Picks